Drug Profile


Alternative Names: BL-3010

Latest Information Update: 29 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gevys Pharmaceuticals
  • Developer BioLineRx
  • Class Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 29 Sep 2015 No recent reports on development identified - Phase-I/II for Pain (In volunteers) in Israel (PO)
  • 07 May 2007 BL 3010 is still undergoing phase I/II development.
  • 30 Sep 2006 Phase-I/II clinical trials in Pain (In volunteers) in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top